CN Patent

CN116987072A — 化合物及其应用

Assigned to Wuhan Chengrui Biomedical Technology Co ltd · Expires 2023-11-03 · 3y expired

What this patent protects

本发明涉及一种式(I)所示结构的化合物、立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药，及其在制备治疗磷脂酰肌醇3‑激酶(PI3Kα)介导的疾病的药物中的应用。

USPTO Abstract

本发明涉及一种式(I)所示结构的化合物、立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药，及其在制备治疗磷脂酰肌醇3‑激酶(PI3Kα)介导的疾病的药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN116987072A
Jurisdiction
CN
Classification
—
Expires
2023-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Chengrui Biomedical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.